Research Paper Volume 13, Issue 8 pp 11336—11351

Figure 2. Effects of TGF-β1 on BMP9-induced osteogenic makers in C3H10T1/2 cells. (A) ALP staining shows the effect of TGF-β1 or LY364947 (TGF-βRI inhibitor) on the ALP activity induced by BMP9. (B) Quantification results of ALP assay show the BMP9-induced ALP activities was affected by TGF-β1 and/or LY364947. (C) Western blotting results show OPN was affected by TGF-β1. (D) Quantification results of western blot assay show OPN was affected by TGF-β1 and/or BMP9. (E) Western blotting analysis showed OPN level was affected by BMP9 and/or LY364947. (F) Quantification results of western blot assay show OPN was affected by BMP9 and/or LY364947. (G) Alizarin Red S assay shows mineralization was affected by TGF-β1, LY364947, and/or BMP9. (H) Quantification results of Alizarin Red S assay show that mineralization was affected by TGF-β1, LY364947, and/or BMP9. ^“**”p < 0.01, ^“#”p < 0.05, and ^“##”p < 0.01.